Celltrion Takes Big Step On Xolair Biosimilar Journey
Phase I Trial For Omalizumab Candidate Began Last Year
Biosimilars major Celltrion has announced further progress on its biosimilar Xolair candidate, as it faces off against the likes of Glenmark to introduce global competition to Genentech/Novartis’ blockbuster cardiovascular biologic.
You may also be interested in...
Data-Backed Celltrion Looks To File Xolair Biosimilar ‘This Year’
Likely frontrunner Celltrion has published 24-week Phase III data for its CT-P39 biosimilar Xolair candidate, which tees up a planned biosimilar filing later this year.
Advanz Agrees Multi-Market Omalizumab Deal With Alvotech
Advanz and Alvotech have struck a deal that will give Advanz exclusive rights to the biosimilars developer’s Xolair (omalizumab) rival in multiple markets around the world.
Selexis And Generium Launch Omalizumab Biosimilar In Russia
Selexis and Generium have claimed the launch of an omalizumab biosimilar in Russia, with their Genolar version of Xolair marking the third biosimilar to be launched by the pair following development with Selexis’ SUREtechnology platform.